Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
|Slideshows|June 14, 2018
Poor Quality of Life for Patients with Pulmonary Hypertension
Author(s)Gregory M. Weiss, MD
Results of a new study identify specific clinical characteristics linked to poor quality of life in patients with PAH.
Advertisement
Advertisement
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
VA Dialysis Tied to Lower Mortality, With Virginia Wang, PhD, MSPH
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
5